2025 年製藥和生技領域的六大成長機會

Top 6 Growth Opportunities in Pharma-Biotech, 2025

出版日期: 2025年02月20日 | 出版商:

Frost & Sullivan | 英文 12 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2025年，製藥和生技產業正進入一個由科學創新、不斷變化的法規和市場壓力融合所塑造的轉型時代。其中一個關鍵挑戰是治療學和藥物核准的持續推進，尤其是個人化醫療的突破性治療有望徹底改變患者護理。腫瘤學仍將是價值最高的治療領域，免疫調節劑將透過現有重磅藥物的銷售實現成長，肥胖症和中樞神經系統將產生新一輪成長。然而，隨著新治療方法的出現，政府和保險公司尋求更具成本效益的解決方案並推動製藥公司提供更多價值，定價壓力正在加劇。

作為回應，製造商正在最佳化生產流程，更加重視高效外包，並引入新的製造技術以滿足不斷成長的全球需求，同時保持成本效益。同時，數位技術和人工智慧（AI）將加速研發、簡化藥物發現、最佳化臨床試驗和個人化治療途徑。這些技術進步對於克服藥物開發的複雜挑戰尤其重要。

此外，新興市場正成為成長的焦點。隨著亞洲、中東和拉丁美洲等地區人口不斷成長，製藥公司正在抓住機會進入這些充滿活力的市場，並利用獨特的監管和經濟狀況為服務不足的患者群體提供創新的解決方案。這些戰略要務的融合正在重塑2025年製藥和生技產業的未來。

本報告研究了全球製藥和生物技術市場，並提供了市場概況、策略要務和成長機會。

策略要務
六大成長機會
成長機會1：放射配體治療促進精準腫瘤學發展
成長機會2：抗體療法徹底改變免疫學和炎症
成長機會三：醫藥市場利用 IT 解決方案提高價格透明度
成長機會#4：醫療副駕駛為臨床試驗服務賦能
成長機會5：亞太地區 CDMO 在製造業格局變化中擴大規模
成長機會#6：透過策略夥伴關係神經保護療法的發展
免責聲明

簡介目錄

Product Code: PFR2-52

Unlocking Growth in Precision Therapeutics, Digital Innovation, Manufacturing, and Emerging Markets

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promise to revolutionize patient care. Oncology will remain the most valuable therapy area, while the immunomodulator segment will grow through existing blockbuster sales, and obesity and CNS will create fresh waves of growth rates. However, as new therapies emerge, drug pricing pressures are intensifying, with governments and insurers pushing for more cost-effective solutions, demanding greater value from pharmaceutical companies.

In response, manufacturers are optimizing production processes, increasing focus on efficient outsourcing, and embracing new manufacturing technologies to meet growing global demand while maintaining cost efficiency. At the same time, digital technologies and artificial intelligence (AI) are poised to accelerate R&D, streamlining drug discovery, optimizing clinical trials, and personalizing treatment pathways. These technological advancements are particularly pivotal in overcoming the complex challenges in pharmaceutical development.

Furthermore, emerging markets are becoming a central focus for growth. As populations in regions such as Asia, the Middle East, and Latin America continue to expand, pharmaceutical companies are seizing opportunities to tap into these dynamic markets, navigating unique regulatory and economic landscapes to deliver innovative solutions to underserved patient populations. These strategic imperatives' convergence is reshaping the future of the pharmaceutical and biotechnology industries in 2025.

Top Growth Opportunities for 2025

Strategic Imperatives
Top 6 Growth Opportunities
Growth Opportunity 1: Radioligand Therapeutics is Fueling Precision Oncology
Growth Opportunity 2: Antibody Therapies are Revolutionizing Immunology and Inflammation
Growth Opportunity 3: The Pharmaceutical Market is Accessing IT Solutions to Ensure Higher Price Transparency
Growth Opportunity 4: Medical Co-pilots are Empowering Clinical Trial Peripheral Services
Growth Opportunity 5: APAC CDMOs are Scaling up Amid the Shifting Manufacturing Landscape
Growth Opportunity 6: Neuroprotective Therapy is Advancing Through Strategic Partnerships
Legal Disclaimer

02-2729-4219

+886-2-2729-4219